Actinium Announces Start of Collaboration to Manufacture IomabTM-B for Phase 3 Clinical Trial and Commercialization

[Business Wire] – Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it made further steps towards centralized current good manufact more

View todays social media effects on ATNM

View the latest stocks trending across Twitter. Click to view dashboard

See who Actinium is hiring next, click here to view